ASCO 2015 Highlights

Encourage Your Patients to Participate! US-Based Clinical Trials That Are Actively Recruiting in Ovarian Cancer
Clinical Trials
August 2024, Vol 15, No 1
Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups.
Read Article
Hematology Oncology Research: The Leading Edge
HOPA Highlights
August 2024, Vol 15, No 1
The variety of ongoing research in cancer has never been more dynamic. Increased understanding into the pathogenesis of cancers, intriguing research into the development of new treatments, the establishment of advanced methods of identifying actionable targets for treatment, and improved strategies for managing adverse events occurring with therapy are among the up-to-the-minute topics in the field.
Read Article
Metrics to Keep in Mind for Value-Based Cancer Care
Value-Based Care
August 2024, Vol 15, No 1
The way value-based care needs to work in oncology is to pay the oncologist for managing all of the problems that occur with cancer and collaborating with other physicians to manage the noncancer illnesses.
Read Article
Alemtuzumab Granted Orphan Drug Status
FDA Approvals, News & Updates
August 2024, Vol 15, No 1
Recently, officials with the FDA granted orphan drug designation (ODD) to alemtuzumab (CLLS52; Cellectis), which is an investigational product used as part of the lymphodepletion regimen administered before UCART22, evaluated in the BALLI-01 clinical trial in relapsed/refractory B-cell acute lymphoblastic leukemia.
Read Article
Pearls for Boosting Clinical Trial Participation in Underrepresented Populations
Pearls for Boosting Clinical Trial Participation in Underrepresented Populations
By Colleen Hall
Clinical Trials
Web Exclusives
Encouraging diverse populations to participate in clinical trials is key as new FDA guidance released.
Read Article
Blood Test for Colorectal Cancer Obtains Approval
FDA Approvals, News & Updates
August 2024, Vol 15, No 1
Shield, Guardant Health has been FDA approved and is now covered by Medicare as the first blood test for primary colorectal cancer (CRC) screening
Read Article
Incidence of Colorectal Cancer Rising in Young Adults
Cancer Awareness, Colorectal Cancer
Web Exclusives
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the United States and is the leading cause of death in men aged <50 years.
Read Article
FDA Granted Second Approval for Epkinly to Treat Patients With Relapsed or Refractory Follicular Lymphoma
FDA Approvals, News & Updates, Lymphoma, Bispecific Antibodies
Web Exclusives
On June 26, 2024, the FDA approved epcoritamab-bysp (Epkinly; Abbvie and Genmab) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after ≥2 lines of prior therapy.
Read Article
Pembrolizumab With Chemotherapy for Some Endometrial Carcinomas Gets Green Light
FDA Approvals, News & Updates
Web Exclusives
FDA officials approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma efficacy of this treatment was evaluated in KEYNOTE-868/NRG-GY018.
Read Article
Quick Quiz: Prostate Cancer Edition
Quick Quiz: Prostate Cancer Edition
Prostate Cancer
Quick Quizzes
According to the National Cancer Institute, prostate cancer is the most common cancer in US men and the second highest cause of cancer death in this patient population. In fact, an estimated 299,010 new cases will be diagnosed in 2024 and approximately 12.9% of men will receive this diagnosis in their lifetime. Thus, a significant portion of your patients and their loved ones will be affected by the disease. As the nation spotlights men’s health awareness this June, test your knowledge on this prevalent disease.
Read Article

Page 6 of 329

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.